Regeneron Pharmaceuticals Investor Presentation — September 2021

Document content

Oncology Investor Event ESMO 2021

S e p t e m b e r 2 0 2 1

This non -promotional presentation is intended for the investor audience and contains investigational dataThis presentation includes forward -looking statements that involve risks and uncertainties relating tofuture events and thefuture performance ofRegeneron Pharmaceuticals, Inc.

(“Regeneron” orthe“Company”), andactual events orresults may differ materially from these forward -looking statements .Words such as“anticipate,” “expect,” “intend,” “plan,” “believe,”

“seek,” “estimate,” variations ofsuch words, andsimilar expressions areintended toidentify such forward -looking statements, although notallforward -looking statements contain these

identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS -CoV-2(thevirus thathascaused theCOVID -19pandemic) on

Regeneron's business anditsemployees, collaborators, andsuppliers andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators’ ability tocontinue toconduct

research andclinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise commercialized byRegeneron and/or itscollaborators

(collectively, "Regeneron’s Products"), andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron’s Products andproduct candidates

being developed byRegeneron and/or itscollaborators (collectively, “Regeneron’s Product Candidates”) andresearch andclinical programs now underway orplanned, including without

limitation Libtayo®(cemiplimab )asmonotherapy orincombination with chemotherapy orother ofRegeneron’s Product Candidates discussed inthispresentation, including fianlimab

(REGN 3767 )and REGN 7075 ,Regeneron’s and itscollaborators’ other oncology programs (including odronextamab (REGN 1979 ),REGN 5458 ,REGN 5093 ,and REGN 5093 -M114),

Regeneron’s and itscollaborators’ other hematology programs, Regeneron’s and itscollaborators’ earlier -stage programs, and theuse ofhuman genetics inRegeneron’s research

programs ;safety issues resulting from theadministration ofRegeneron’s Products and Regeneron’s Product Candidates inpatients, including serious complications orside effects in

connection with theuseofRegeneron’s Products andRegeneron’s Product Candidates inclinical trials ;thelikelihood, timing, andscope ofpossible regulatory approval andcommercial

launch ofRegeneron’s Product Candidates andnew indications forRegeneron’s Products, including without limitation those listed above ;thepossible success ofRegeneron’s oncology

strategy andthelikelihood andtiming ofachieving anyoftheanticipated milestones described inthispresentation ;theextent towhich theresults from theresearch and development